

Date 2.6.2020				Deadline			
CONTACT]					
Organisation		CHU-Nantes		Department			
Contact person		Pr. Antoine ROQUILLY		Email	antoine.roquilly@chu-nantes.fr		u-nantes.fr
City		Nantes		Website			
Country		France					
Organisation Research organisation type	Res Un Coi	search Organisation iversity mpany ier (University Hospital)	and M Enter	ur company a Medium Sizec rprise (SME*) ber of employ	1 ?	TYES	⊠ NO

Your enterprise is an SME if:

- it is engaged in economic activity

- it has less than 250 employees

- it has either an annual turnover not exceeding €50M, or an balance sheet total not exceeding €43M - it is autonomous

For the definition of SMEs, look at: <u>http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en</u>

Short introduction of key areas of institute's research:

For more than 10 years, EA3826 laboratory's team has been studying the mechanisms of postcritical immunosuppression and its impact on hospital acquired pneumonia (HAP). Nantes University Hospital (CHU-Nantes) plans to contribute the following expertise and assets:

- preexisting cohorts and biocollections developed by CHU-Nantes, including a biological cohort of more than 500 critically ill patients at risk of acute respiratory distress syndrome has been constitued. Nasopharyngeal swab and plasma samples are stored in the Nantes University Hospital biobank.
- Collections of samples and clinical data of patients with COVID-19 admitted to CHU-Nantes

Former participation in an FP European project?	⊠ YES (H2020 project)		
Project title / Acronym:	Host-targeted Approaches for the Prevention and the treatment of Hospital- Acquired Pneumonia (HAP2)		
Activities performed:	This network enables randomized clinical trials evaluating immunotherapies in pneumonia.		

Expertise / Commitment offered



Description of your	We are offering ability to investigate host-pathogens interactions in the lungs of					
expertise:	critical patients through :					
	 Collections of samples and clinical data of critical-ill patients Study of virome and respiratory microbiome alterations in patients with 					
	COVID-19 pneumonia (monitoring of viral, viral metagenomics, virome, metabolome)					
	3) High-dimensional characterization of immune responses during COVID-19					
	pneumonia (Real-time high-dimensional monitoring of circulating immune cells,					
	serum cytokine/chemokine profiles, comprehensive gene expression profiling)					
Keywords specifying	ywords specifying Cohort, biological samples, clinical data, biomarker, virome, microbiome,					
your expertise: immunity, host-pathogens interactions						
	······································					
Commitment offered:						
communent onered.	🗵 Research 📃 Demonstration 📃 Training					
	Technology Dissemination Other:					
Interested in	Research & Innovation Innovation Action					
participation in Ac	tion Instrument					
project types:						
Work Programme res	earch areas: indicate your interest					
SC1-PHE-CORONAVIRUS-2020-2						
Call topic(s):						
,	IS-2020-2D "Pan-European COV/ID-19 cohorts" topic					

SC1-PHE-CORONAVIRUS-2020-2D "Pan-European COVID-19 cohorts" topic
SC1-PHE-CORONAVIRUS-2020-2E "Networking of existing EU and international cohorts of relevance to
COVID-19" topic
·

Do you have other	Pr. Régis Josien, CRTI – UMR1064, Nantes University, France :
partners for this	immunophenotyping
topic (which	Dr Jérémie Poschmann, CRTI – UMR1064, Nantes University, France :
partners/country)?	bioinformatic analyses

Profile of partner sought

Role	technology development	research	□ training
	dissemination	demonstration	other
Country /region			
Expertise required			

I agree with the publication of this document and my contact data: 🗵 YES 🗆 NO